Medizencare
1 known investors
Medizencare provides personalized genomic analysis and precision healthcare services based on individual DNA data for consumers interested in smart health management.
Also known as Medizen Humancare ยท MEDIZEN HUMANCARE INC. ยท ๋ฉ๋์ ํด๋จผ์ผ์ด
Investors ยท 1
Company profile
researched Aug 2026MEDIZEN HUMANCARE INC. (๋ฉ๋์ ํด๋จผ์ผ์ด) is a South Korean bio company specializing in personalized genomic analysis for disease prediction and precision healthcare. Its core service, M-CHECK (My Genome Check), analyzes single nucleotide polymorphisms scientifically associated with specific diseases and combines the results with environmental factors such as exercise, diet and lifestyle habits to estimate an individual's risk of disease. The company states M-CHECK can currently predict approximately 80 types of diseases and drug reactions, with the item list changing according to approvals from the Korea Centers for Disease Control and Prevention, and that the service can be configured per inspection item requested by medical institutions.
Alongside M-CHECK, the company markets MELTHY, a direct-to-consumer genomic testing kit for non-medical institutions launched in 2016, and MELTHY ASIA, a version aimed at Asian markets including Japan, the Philippines, Mongolia, China, Taiwan, Vietnam, Singapore and Indonesia. Stated service areas include personalized health examination through genomic analysis, genome-based drug information, and design and analysis of exercise, skin care and life health programs. Its R&D activity covers development and clinical trials of disease diagnostic kits (cancer, myocardial infarction, stroke), diagnostic chips for genetic variation, and construction of an integrated clinical and genetic diagnostic database.
The company describes a strategy of building genetic resource and big data banking for various ethnic groups including Koreans, discovering candidate materials for genomic drugs, and integrating IT and artificial intelligence with specialist medical consultation across pharmacology, skin care, nutrition and exercise.
Founding story
MEDIZEN HUMANCARE Inc. was founded in July 2012 by Dr. Shin, a PhD in genetics and a former professor at Yonsei University, with the aim of becoming a personalized healthcare company based on genomic big data. The M-CHECK genomic analysis system for disease prediction was launched in the same month.
Business model
The company sells genomic testing and analysis services, supplying disease-prediction genome analysis to medical institutions, clinics, pharmacies, government agencies and affiliated organizations, and direct-to-consumer test kits under the MELTHY brand. It also develops and aims to commercialize molecular diagnostic kits, and states an intention to enter platform and data-selling businesses based on its accumulated bio big data.
Revenue derives from genomic analysis services and genetic testing kits sold to medical and health-check institutions and to consumers, with planned expansion into data sales and platform services built on its genomic database.
Traction
The company reports having accumulated 810,000 bio big data records with a stated target of 1 million by 2022, and offers prediction across about 80 diseases and drug reactions. It has been listed on the KONEX exchange since January 2016.
Latest developments
Corporate governance notices posted on the company website include an audit report for the 10th fiscal year in March 2022, a notice of resolution to convene a shareholders' meeting in March 2023, and a notice of the record date for shareholder determination for an extraordinary general meeting in November 2023. Through InvestKOREA the company has sought USD 5-10 million of investment for a 10% share, with the stated purpose of advancing disease prediction genetic testing by establishing local joint ventures overseas.
โธFull profile โ market position, technology, go-to-market, geography, history
Market position
The company describes itself as a leading Korean genetic testing company, having begun work with health check-up centers such as KMI, and states it holds the largest bio big data set among Korean genetic companies. It received a grand prize in the genomic testing field for leading South Korean companies in August 2016 and a Hankyung brand award in healthcare in November 2016, and was certified as a Grade P institution for accuracy in genetic testing in 2015 and 2017.
Differentiation is stated in terms of a portfolio of 24 patents on a universal algorithm applicable across diseases and a gene network system, a two-stage model combining genetic and environmental factors, and a large accumulated bio big data set relative to Korean peers.
Technology
The company's analysis selects and evaluates genetic mutations (SNPs) among roughly 10 million human variants that have been scientifically verified as associated with specific diseases, then layers environmental and lifestyle factors on top through a two-stage model of genetic and environmental effects. It reports holding 24 patents covering a universal algorithm applicable to all diseases and a gene network system, and operates a registered genetic testing laboratory and research institute approved in 2013. R&D includes diagnostic chips for genetic variation and an integrated database linking clinical and genetic information.
Go-to-market
Sales run through health check-up centers and medical institutions, including work with the Korean health screening operator KMI, complemented by direct-to-consumer test kits and stated interest in overseas expansion via local joint ventures involving technology transfer and equity agreements based on technology investment.
Medical institutions, clinics, pharmacies, government agencies and affiliated organizations, health check-up centers, and individual consumers seeking personalized health management.
Geography
Headquartered in South Korea with a website in Korean, English and Chinese. MELTHY ASIA targets Asian markets including Japan, the Philippines, Mongolia, China, Taiwan, Vietnam, Singapore and Indonesia, and the company states an intent to expand into China, the Americas and Europe.
History
Founded in July 2012 with the launch of M-CHECK, the company registered a corporate R&D center with the Korea Industrial Technology Association in October 2012. In 2013 it registered a Genetic Testing Center, Genetic Research Center and Institutional Bioethics Committee with the Korea Centers for Disease Control and Prevention under the Ministry of Health and Welfare, and was registered as a venture company in September 2013. It was selected as a Family Company by the Small and Medium Business Corporation in January 2014, became a full member of the Korea Genome Industry Council at the Korea Biotechnology Industry Organization in June 2015, and obtained ISO 9001 certification in August 2015. The company listed on the KONEX exchange on 26 January 2016 and in the same year received the Grade P (highest) rating for accuracy evaluation in genetic testing, launched the MELTHY DTC kit in October and MELTHY ASIA in December. It was again certified Grade P in January 2017. Corporate notices published on its website include an audit report for the 10th fiscal year (March 2022), a resolution to convene a shareholders' meeting (March 2023) and a record date notice for an extraordinary shareholders' meeting (November 2023).
Compiled by commissioned research from 4 cited public sources โ announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed โ not independently audited.
Timeline ยท 12
launches, deals, and filingsKit targeted at the Asian region including Japan, the Philippines, Mongolia, China, Taiwan, Vietnam, Singapore and Indonesia.
Launched MELTHY, a domestic genomic testing kit for non-medical institutions (DTC).
Certified as a Grade P institution for accurate evaluation in genetic testing for 2015.
Registered as a venture company with the Korea Technology Finance Corporation and Korean Venture Capital Association.
Registered a Genetic Testing Center, Genetic Research Center and Institutional Bioethics Committee with the Korea Centers for Disease Control and Prevention under the Ministry of Health and Welfare.
MEDIZEN HUMANCARE Inc. was founded and launched M-CHECK, a genomic analysis system for disease prediction.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
โธResearch sources ยท 4
primary sources listed
- Medizencaremedizencare.com ยท web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medizencare do?
- Korean bio company providing personalized genomic analysis services that predict individual disease risk from DNA data.
- Who are Medizencare's investors?
- Medizencare's investors include Kiwoom Investment.